Pyxis Oncology PYXS 深 滬
等待開盤 11-04 09:30:00 美东时间
1.64
-0.050
-2.96%
華盛通- 最 高1.76
- 今 開1.72
- 成交量 64.58万股
- 最 低 1.62
- 昨 收 1.69
- 總市值 1.96亿
- 52周最高 5.55
- 市盈率 靜 --
- 換手率 0.54%
- 52周最低 1.03
- 委 比 -9.92%
- 總股本 1.20亿
- 歷史最高 19.00
- 量 比 0.77
- 振 幅 8.28%
- 歷史最低 0.8332
- 每 手 1
- 風險率 1.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pyxis Oncology收跌6.63%，成交额153.14万美元
11月3日，Pyxis Oncology（PYXS）收跌6.63%，报1.69美元，成交额153.14万美元，市值2.02亿美元。 行情数据 • 开盘价：1....
11-03 07:38
Pyxis Oncology To Present Late-Breaking Oral Data On MICVO Monotherapy In Previously Treated Recurrent/Metastatic Head And Neck Cancer At EORTC-NCI-AACR Symposium
Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent/metastatic (R/M) head and neck squamous ...
10-27 20:47
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Pyxis Oncology will present late-breaking data on micvotabart pelidotin (MICVO) monotherapy for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) at the 38th EORTC-NCI-AACR Symposium in Barcelona, November 18-20, 2026. An oral presentation by Faye M. Johnson, M.D., Ph.D., will discuss Phase 1 study results, while two posters will highlight preclinical research on MICVO's mechanism of action and combination therapy in HNSCC models...
10-27 12:45
Pyxis Oncology收涨0.6%，成交额109.28万美元
10月27日，Pyxis Oncology（PYXS）收涨0.6%，报1.69美元，成交额109.28万美元，市值2.02亿美元。 行情数据 • 开盘价：1....
10-27 06:40
Pyxis Oncology收跌6.67%，成交额153.07万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:44
Pyxis Oncology Terminates $150M ATM Offering, Says As Of The Date Of This Supplement, We Have Not Sold Any Shares Of Our Common Stock Pursuant To The Sales Agreement
PYXIS ONCOLOGY, INC. Common Stock This Supplement No. 1 to Prospectus Supplement (this "Supplement") supplements and amends the Prospectus Supplement dated November 26, 2025 (the "Prospectus Supplement"). This Supplement should be read in conjunction with the Prospectus Supplement and the Prospectus...
09-30 04:24
Pyxis Oncology Announces Proposed Public Offering
Pyxis Oncology has launched a public offering of its common stock and warrants, with proceeds to fund its lead clinical program, MICVO, targeting recurrent/metastatic head and neck squamous cell carcinoma. The offering includes common stock, pre-funded warrants, and accompanying common warrants exercisable upon shareholder approval of a charter amendment. The warrants' exercise is contingent on the amendment's effectiveness and the release of ove...
09-29 20:24
美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug
Pyxis Oncology Inc. (NASDAQ:PYXS) on Wednesday shared updated data from its Phase 1 trial evaluating micvotabart pelidotin (MICVO). The ongoing global study tested the drug as a monotherapy for patients facing second-line and beyond recurrent or metastatic head and neck squamous cell carcinoma. Prom...
09-10 01:42
